CASP3 and diabetic kidney disease: A class of GSDME-derived inhibitors containing the core structure of DMPD or DMLD was developed, and Ac-DMPD-CMK and Ac-DMLD-CMK could directly bind to and inhibit the catalytic domains of caspase-3, blocking the cleavage function on GSDME and preventing pyroptosis in the liver, implying a therapeutic role in DKD Treatment with Ac-DMLD-CMK, a peptide targeting caspase-3/GSDM [145].